# US 2024/0252691 A1 · Magnetic nanoparticles for image diagnosis and contrast medium for image diagnosis

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0252691 A1
- Document ID: US20240252691A1
- Status: Published application
- Kind: A1
- Application number: 18/561,702
- Filed: 2022-05-12
- Published: 2024-08-01
- Earliest claimed: 2021-05-18
- Assignees: Osaka University
- Applicants: Osaka University
- Inventors: Satoshi SEINO; Hiroto IKEHATA; Takami TOMIYAMA; Tomohiro UMEDA; Akihiro IZAWA
- Web page: https://patentgrep.com/patent/US20240252691A1

## CPC

- A61K 49/183: {having a (super)(para)magnetic core coated or functionalised with an inorganic material or being composed of an inorganic material entrapping the MRI-active nucleus, e.g. silica core doped with a MRI-active nucleus}
- A61K 49/186: {the organic macromolecular compound being polyethyleneglycol [PEG]}
- A61B 5/0042: {for the brain}
- A61B 5/0515: Magnetic particle imaging
- A61B 5/055: involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
- A61B 5/4088: {Diagnosing of monitoring cognitive diseases, e.g. Alzheimer, prion diseases or dementia}
- A61B 5/4839: {combined with drug delivery}
- A61B 5/4848: {Monitoring or testing the effects of treatment, e.g. of medication}
- A61B 5/7425: {Displaying combinations of multiple images regardless of image source, e.g. displaying a reference anatomical image with a live image}
- A61K 47/02: Inorganic compounds
- A61K 47/10: Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A61K 47/22: Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
- A61K 49/1833: {having a (super)(para)magnetic core coated or functionalised with a small organic molecule (oligomeric, polymeric, dendrimeric A61K49/1851)}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61B: DIAGNOSIS; SURGERY; IDENTIFICATION (usefulness limited to only animals A61D)

## Abstract

The purpose of the present invention is to provide a contrast medium using a paramagnetic metal that accumulates at an abnormal protein deposition or aggregation site in the brain. Magnetic nanoparticles for image diagnosis which comprise magnetic iron oxide particles, gold fine particles supported on the surface of the magnetic iron oxide particles, a polymer chain attached to the gold fine particles and a molecule directing for a neurodegenerative disease-related protein and attached to at least a part of the polymer chain, and which are to be administered transnasally. These magnetic nanoparticles for image diagnosis are useful as an active ingredient of a contrast medium that accumulates at an abnormal protein deposition or aggregation site in the brain.

## Claims

### Claim 1

A magnetic nanoparticle for image diagnosis, comprising:
a magnetic iron oxide particle;
a gold fine particle supported on a surface of the magnetic iron oxide particle;
a polymer chain bonded to the gold fine particle; and
a directed group for a neurodegenerative disease-related protein bonded to at least a part of the polymer chain.

### Claim 2 (depends on 1)

The magnetic nanoparticle for image diagnosis according to claim 1, wherein the directed group for a neurodegenerative disease-related protein is bonded to 1 to 50 mol % of the polymer chain.

### Claim 3 (depends on 1)

The magnetic nanoparticle for image diagnosis according to claim 1, wherein the neurodegenerative disease-related protein is amyloid β.

### Claim 4 (depends on 1)

The magnetic nanoparticle for image diagnosis according to claim 1, wherein the polymer chain has a weight average molecular weight of 2,000 to 300,000.

### Claim 5 (depends on 1)

The magnetic nanoparticle for image diagnosis according to claim 1, having an average hydrodynamic diameter of 50 to 200 nm.

### Claim 6 (depends on 1)

The magnetic nanoparticle for image diagnosis according to claim 1, wherein the polymer chain is polyethylene glycol.

### Claim 7 (depends on 1)

A contrast medium for image diagnosis comprising the magnetic nanoparticle for image diagnosis according to claim 1.

### Claim 8 (depends on 1)

A method of treating a subject comprising administering the magnetic nanoparticle according to claim 1 to the subject.

### Claim 9 (depends on 8)

The method according to claim 8, wherein the magnetic nanoparticle is nasally administered.

### Claim 10 (depends on 1)

The method according to claim 1, wherein the subject suffers from a neurodegenerative disease.
